Cantor Fitzgerald lowered its price target on Biogen (NASDAQ: BIIB) to $272.00 (from $289.00) while maintaining a Neutral rating.

Analyst PT Change

Biogen (BIIB) PT Lowered to $423 at Mizuho SecuritiesApril 30, 2018 1:01 AM Biogen (BIIB): Mixed Results Keep Shares Steady For Now - NomuraApril 25, 2018 8:50 AM Biogen (BIIB) PT Lowered to $311 at RBC CapitalApril 25, 2018 7:43 AM Biogen (BIIB) PT Raised to $369 at Morgan StanleyApril 25, 2018 7:24 AM Biogen (BIIB) PT Lowered to $375 at OppenheimerApril 25, 2018 7:15 AM Biogen (BIIB) PT Lowered to $325 at Leerink PartnersApril 25, 2018 6:37 AM Biogen (BIIB) PT Lowered to $385 at GuggenheimApril 25, 2018 2:03 AM UPDATE: Baird Upgrades Biogen (BIIB) to OutperformApril 25, 2018 1:08 AM UPDATE: Goldman Sachs Downgrades Biogen (BIIB) to BuyApril 25, 2018 12:56 AM Biogen (BIIB) PT Lowered to $353 at Piper JaffrayApril 24, 2018 1:30 PM